Boostrix Vaccine Description - 2022
Boostrix is a vaccine for the prevention of tetanus, diphtheria, and pertussis in people who are at least 10 years old. This vaccine is also available for adults who need a booster. Most people in these age groups require only one Tdap shot for added protection against these diseases.
Boostrix contains inactive substances produced by the bacteria that cause tetanus and diphtheria. Boostrix also contains fragments of the bacteria that cause pertussis (whooping cough).
None of these substances or bacterial fragments can cause disease.
Boostrix Vaccine Indication
Boostrix is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis for individuals aged 10 years and older.
Boostrix Vaccine Dosage
Boostrix is administered as an intramuscular injection into the upper arm muscle.
Boostrix is approved for use as a single dose in individuals 10 years of age and older.
Boostrix is generally given whenever a booster dose of diphtheria and tetanus vaccine is required and where a booster for pertussis is desired.
It may also be given in the case of a tetanus-prone injury where a booster for diphtheria and pertussis is also required, provided no previous dose of tetanus vaccine was given within five years previously.
Boostrix Vaccine News - 2022
February 9, 2022 - GSK reported Boostrix sales grew 9% AER, 14% CER to £521 million, largely driven by demand recovery and tender volumes in International, as well as higher demand and share in the US.
January 6, 2021 - SK Bioscience and GlaxoSmithKline (GSK) signed a co-promotion and distribution agreement. Under the contract, the Korean company, SK Bioscience will sell and distribute five types of vaccines developed by GSK, expanding its share in the local vaccine market. The five vaccines are Boostrix to prevent TDAP (Tetanus, Diphtheria, and Pertussis), Menveo against meningococcal disease, Havrix 1440 against Hepatitis A, Priorix against measles and mumps, and Cervarix against cervical cancer.
Boostrix Vaccine Clinical Trials
GSK's Boostrix vaccine has been involved in over 140 clinical trials.